Trial Profile

A Phase I Study of DS-8201a in Combination With Olaparib in HER2-Expressing Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olaparib (Primary) ; Trastuzumab-deruxtecan (Primary)
Indications Carcinoma; Endometrial cancer; Ovarian cancer; Solid tumours; Uterine cancer
Focus Adverse reactions; Biomarker

Most Recent Events

19 Apr 2026 According to Dana-Farber Cancer Institute Media Release, Patients in module 1 and module 3 experienced dose-limiting toxicities, related to low blood counts. Enrollment in these groups was halted.
19 Apr 2026 According to Dana-Farber Cancer Institute Media Release, data from the trial were presented at the AACR Annual Meeting 2026, held April 17-22, in San Diego, Calif.
19 Apr 2026 Results presented in the Dana-Farber Cancer Institute Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com